Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 8:42:101039.
doi: 10.1016/j.gore.2022.101039. eCollection 2022 Aug.

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma

Mary Towner  1 , Karen Novak  1 , Young Kwang Chae  2 , Daniela Matei  1   3
Affiliations
Case Reports

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma

Mary Towner et al. Gynecol Oncol Rep. .

Abstract

Neuroendocrine carcinoma of the cervix is a rare subtype of cervical cancer with a poor prognosis. Primary treatment of this disease involves a combination of surgery, chemotherapy, and radiation. The majority of patients will experience disease recurrence, for which there exist no treatment guidelines. Because of histologic similarities, small cell lung cancer has often informed management of extrapulmonary neuroendocrine carcinomas. Immunotherapy regimens, including a combination of ipilimumab and nivolumab, have been shown to have activity in small cell lung cancer. In this report, we present the cases of 3 patients with recurrent neuroendocrine carcinoma of the cervix who experienced durable response to a combination of ipilimumab and nivolumab.

Keywords: Immunotherapy; Ipilimumab; Neuroendocrine carcinoma of the cervix; Nivolumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: YKC has received grants from Abbvie, BMS, Biodesix, Lexent Bio, and Freenome and consulting fees and/or honoraria from Roche/Genentech, AstraZeneca, Foundation Medicine, Counsyl, Neogenomics, Guardant Health, Boehringer Ingelheim, Biodesix, Immuneoncia, Lilly Oncology, Merck, Takeda, Lunit, Jazz Pharmaceuticals, and Tempus. DM has received consulting fees from Merck, GSK, Seagan, and the GOG Foundation. MT and KN have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

References

    1. Alejo M., Alemany L., Clavero O., Quiros B., Vighi S., Seoud M., Cheng-Yang C., Garland S.M., Juanpere N., Lloreta J., Tous S., Klaustermeier J.E., Quint W., Bosch F.X., de Sanjosé S., Lloveras B. Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases. Papillomavirus Res. 2018;5:134–142. - PMC - PubMed
    1. Al-Toubah T., Halfdanarson T., Gile J., Morse B., Sommerer K., Strosberg J. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open. 2021;7(1) doi: 10.1016/j.esmoop.2021.100364. - DOI - PMC - PubMed
    1. Antonia S.J., López-Martin J.A., Bendell J., Ott P.A., Taylor M., Eder J.P., Jäger D., Pietanza M.C., Le D.T., de Braud F., Morse M.A., Ascierto P.A., Horn L., Amin A., Pillai R.N., Evans J., Chau I., Bono P., Atmaca A., Sharma P., Harbison C.T., Lin C.-S., Christensen O., Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895. - PubMed
    1. Castle P.E., Pierz A., Stoler M.H. A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. Gynecol. Oncol. 2018;148(2):422–429. doi: 10.1016/j.ygyno.2017.12.001. - DOI - PubMed
    1. Frazier S.R., Kaplan P.A., Loy T.S. The pathology of extrapulmonary small cell carcinoma. Semin. Oncol. 2007;34(1):30–38. doi: 10.1053/j.seminoncol.2006.11.017. - DOI - PubMed

Publication types

LinkOut - more resources